Search Results for: nocturnal akinesia, dystonia, cramps score nadcs

Parkinson's Disease Neuropsychiatric Features And Fatigue Respond To Transdermal Rotigotine

Posted: Published on April 29th, 2012

Editor's Choice Main Category: Parkinson's Disease Article Date: 28 Apr 2012 - 6:00 PDT email to a friend printer friendly opinions Current Article Ratings: In the EU, Neupro (rotigotine) is approved for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as a monotherapy, i.e. without levodopa, or in combination with levodopa over the course of the disease until the late stages, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or on-off fluctuations). It is also approved in the EU for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults. Parkinson's disease (PD) is a progressive, chronic neurodegenerative disease that affects about 1 in every 500 people. In the UK, 127,000 people suffer from PD, which is mainly characterized by problems with 'motor symptoms', of which the most predominant one is body tremor. Over 90% of people with Parkinson's disease suffer from NMS or non-motor symptoms like sleep disturbance, mood disorders, pain and gastro-intestinal problems, which are a major cause of disability, but because they are either embarrassed or unaware that the symptoms are associated with Parkinsons, they often fail to … Continue reading

Posted in Parkinson's Treatment | Comments Off on Parkinson's Disease Neuropsychiatric Features And Fatigue Respond To Transdermal Rotigotine